Advances in antiviral therapy

Current Opinion in Pediatrics

Volumn 11, Issue 1, 1999, Pages 21-27

  Zerr, Danielle M ^a   Frenkel, Lisa M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMIQUIMOD; IMMUNOGLOBULIN; LAMIVUDINE; PALIVIZUMAB; PENCICLOVIR; PROBENECID; RIBAVIRIN; UNCLASSIFIED DRUG; VALACICLOVIR;

BONE MARROW SUPPRESSION; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG DEVELOPMENT; FEVER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; INFANT; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEWBORN; ORAL DRUG ADMINISTRATION; PEDIATRICS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; THROMBOCYTOPENIC PURPURA; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VOMITING; WART VIRUS;

ANTIVIRAL AGENTS; CHILD; HUMANS; VIRUS DISEASES;

EID: 0032993171     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199902000-00005     Document Type: Review

References (51)

1. Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T, et al.: Postexposure prophylaxis of vericella in family contact by oral acyclovir [see comments]. Pediatrics 1993, 92:219-222.
2. Lin TY, Huang YC, Ning HC, Hsueh C: oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997, 16:1162-1165. This trial evaluates oral acyclovir as a prophylactic agent for primary varicella zoster infection.
3. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, et al.: Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991, 324:450-454.
4. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, et al.: Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996, 15:247-254.
5. Scott LL, Alexander J: Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy. Am J Perinatol 1998, 15:57-62.
6. Randolph AG, Hartshorn RM, Washington AE: Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol 1996, 88:603-610.
7. Brocklehurst P, Kinghorn G, Carney O, Helsen K, Ross E, Ellis E, et al.: A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998, 105:275-280.
8. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD Jr.: Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996, 87:69-73.
9. Acosta EP, Fletcher CV: Valacyclovir. Pharmacotherapy 1997, 31:185-191.
10. Tyring SK, Douglas JM, Corey L, Spruance SL, Esmann J: A randomized, placebo-controlled comparison of roal valacyctovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol 1998, 134:185-191. This randomized controlled trial compared the use of valacyclovir and acyclovir for the treatment of recurrent genital herpes.
11. Fife KH, Barbarash RA, Rudolph T, Degregorio B, Roth R, Valaciclovir International Herpes Simplex Virus Study Group: Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: results of an international, multicenter, double-blind, randomized clinical trial. Sex Transm Dis 1997, 24:481-486. This randomized, controlled trial compared the use of valacyclovir and acyclovir for the treatment of a first episode of genital herpes.
12. Mertz GH, Loveless MO, Levin MJ, Kraus SJ, Fowler SL, Goade D, Tyring SK: Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. Arch Intern Mad 1997, 157:343-349.
13. Schacker T, Hu H, Koelle DM, Zeh J, Saltzman R, Boon R, et al.: Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med 1998, 128:21-28.
14. LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB: Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesioin with intravenous cidofovir. Clin Infect Dis 1998, 26:512-513.
15. Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, et al.: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997, 175:180-186. This manuscript presents the phase II evaluation of ganciclovir for the treatment of congenital CMV and also discusses the importance of finding effective therapies for this potentially devastating condition.
16. Frenkel LM, Dankner W, Capparelli E, Wei LJ, Xu J, Spector S, et al.: A pharmacokinetic (PK) study of oral ganciclovir (GCV) in HIV and cytomegalovirus (CMV) infected children [abstract]. XI International Conference on AIDS; 1996. [WEB550]
17. Musch DC, Martin DF, Gordon JF, Davis MD, Kupermann BD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Mad 1997, 337:83-90. This randomized, controlled trial evaluates ganciclovir implants for the treatment of cytomegalovirus retinitis.
18. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, et al.: Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the ea of potent antiretroviral therapy. Arch Intern Med 1998, 158:957-969. This paper provides guidelines for the treatment of cytomegalovirus disease in patients with AIDS.
19. Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DB, et al.: Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997, 126:257-263.
20. Lalezari JP, HOlland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, et al.: Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:339-344.
21. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, et al.: (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995, 171:788-796.
22. Taskintuna I, Rahhal FM, Arevalo JF, Munguia D, Banker AS, DeClercq E, Freeman WR: Low-dose intravitreal cidofocir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1997, 104:1049-1057.
23. Rahhal FM, Arevalo JF, Munguia D, Taskintuna I, delaPaz EC, Azen SP, Freeman WR: Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996, 103:1078-1083.
24. Taskintuna I, Rahhall FM, Rao NA, Wiley CA, Mueller AF, Banker AS, et al.: Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997, 104:1827-1836.
25. Sadler M, Morris-Jones S, Nelson M, Gazzard BG: Successful treatment of cytomegalovirus encephalitis in an AIDS patients using cidofovir. AIDS 1997, 11:1293-1294.
26. Blick G, Whiteside M, Griegor P, Hopkins U, Garton T, LaGravinese L: Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis 1998, 26:191-192.
27. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL et al.: The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV_infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997, 176:1517-1523.
28. Committee on Infectious Diseases: Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 1997, 99:645-650.
29. The PREVENT Study Group: Reduction of respiratory sycytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93-99. This large, randomized, controlled trial evalutes the use of RSV-IGIV for prophylaxis against hospitalization for RSV.
30. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al.: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993, 329:1524-1530.
31. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE: A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med 1998, 152:358-366. This manuscript describes a method that can be used to evaluate therapies and their treatment effect by using available evidence.
32. Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EAF, Rosas AJ, Lepow M, et al.: Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997, 100:937-942.
33. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang S-C, Dormitzer M, et al.: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
34. The Impact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. This randomized, controlled trial is the first large study to evaluate the use of palivizumab for prophylaxis of hospitalization for RSV.
35. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al.: Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997, 113:1258-1263.
36. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D: Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997, 64:1624-1627.
37. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kapa R: Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997, 63:393-396.
38. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, et al.: Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996, 348:1212-1215.
39. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al.: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Mad 1998, 339:61-68. This phase III trial is the first large study to evaluate the use of lamivudine for the treatment of chronic hepatitis B.
40. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR: Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997, 63:1415-1419.
41. Nicoll A, Locarnini S: Review: present and future directions in the treatment of hepatitis B infection. J Gastroenterol Hepatol 1997, 12:843-854.
42. Melegari M, Scaglioni PP, Wands JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628-633.
43. Yoshida EM, Ma MM, Davis JE, Fischer KP, Knetman NM, Erb SR, Tyrrell DL, Bain VG: Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow-up. Hepatology 1998, 12:125-129.
44. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al.: Re-treatment of chronic hepatitis C with consensus interferon [published erratum appears in Hepatology 1998, 28(2):599]. Hepatology 1998, 27:1136-1143.
45. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al.: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997, 26:961-966.
46. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O: Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group [see comments]. Lancet 1998, 351:83-87.
47. Syed TA, Goswami J, Ahmadpour OA, Ahmed SA: Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998, 25:309-313.
48. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML, et al.: Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998, 42:789-794.
49. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA: Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998, 134:25-30.
50. Meadows KP, Tyring SK, Pavia AT, Rallis TM: Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997, 133:987-990.
51. Snoeck R, Wellens W, Desloovere C, VanRanst M, Naesens L, DeClercq E, Feenstra L: Treatment of severe laryngeal papillomatosis with intralesioinal injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine]. J Med Virol 1998, 54:219-225. This case series of 17 patients provides early data of the potential utility of cidofovir for the treatment of laryngeal papillomatosis.